Goldman Sachs upgraded Ryan Specialty (RYAN) to Buy from Neutral with a price target of $81, up from $74. The company will offer the greatest organic growth, total revenue growth, and margin expansion opportunity in the insurance brokerage coverage universe over the next several years, with a “reasonable valuation considering better-than-peer fundamentals,” the analyst tells investors in a research note. The firm expects investors to be forward-looking to the second half of 2025 and beyond, where it believes Ryan can maintain its organic growth gap versus retail insurance brokers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYAN:
- Ryan Specialty’s Earnings Call: Strong Growth Amid Challenges
- Strong Organic Growth and Strategic Investments Drive Buy Rating for Ryan Specialty Group
- Ryan Specialty Group Reports Strong Revenue Growth Amidst Net Loss
- Ryan Specialty reports Q1 adjusted EPS 39c, consensus 39c
- Ryan Specialty sees FY25 organic revenue growth rate 11%-13%